ImmunologyTier 2Medical Sciences concept

Factor VIII inhibitor development risk by product type

Core concept

An inhibitor is an alloantibody (IgG4, non-complement-fixing) against infused factor VIII in a patient whose own gene makes none
- Recognised as foreign because the patient has never been tolerised to FVIII
Incidence ~25-30% of previously untreated patients (PUPs) with severe haemophilia A, almost always within the first 20-50 exposure days
Far lower in haemophilia B (~3-5%), but factor IX inhibitors carry anaphylaxis and nephrotic syndrome on re-exposure

Risk by product

Plasma-derived FVIII containing von Willebrand factor carries a LOWER inhibitor risk than recombinant FVIII in previously untreated patients (SIPPET randomised trial: ~87% relative increase with recombinant)
- VWF is thought to shield immunodominant FVIII epitopes (the C2 and A2 domains) from antigen-presenting cells
- The finding is specific to PUPs; it does not apply to previously treated patients, and product choice also weighs access, purity, half-life and patient preference

Other risk factors

Genetic	Treatment-related
Severe haemophilia (FVIII <1%)	Intensive first exposure - high-dose, continuous infusion, surgery, major bleed
Null mutations: large deletions, nonsense, intron 22 inversion (no endogenous protein at all)	Danger signal at first exposure - infection, vaccination, tissue injury
Missense/mild disease -> low risk	Early prophylaxis with regular low doses may be protective
African ancestry, family history of inhibitor
HLA class II and IL-10, TNFA, CTLA4 polymorphisms

Detection and quantification

Bethesda assay (Nijmegen-modified) - 1 Bethesda Unit inactivates 50% of FVIII in normal plasma

	Definition	Implication
Low-titre	<5 BU	Overcome with high-dose FVIII
High-titre	>=5 BU (or an anamnestic rise)	FVIII will not work - use a bypassing agent

Screen with a mixing study: APTT fails to correct, and correction WORSENS after 1-2 h incubation at 37 degrees (time- and temperature-dependence distinguishes a FVIII inhibitor from a lupus anticoagulant, which corrects immediately or not at all)
Acquired haemophilia A is the autoantibody counterpart - older adults, malignancy, postpartum, autoimmune disease; type II kinetics so residual FVIII activity is measurable despite a high titre

Bleeding with a high-titre inhibitor
- Bypassing agents: recombinant factor VIIa or FEIBA (activated prothrombin complex concentrate)
- Do not give both together - thrombotic risk; and FEIBA plus emicizumab caused thrombotic microangiopathy in trials
Emicizumab - bispecific antibody bridging factor IXa and factor X, mimicking FVIII's cofactor role
- Works irrespective of inhibitor status, given subcutaneously, weekly to monthly - it has transformed prophylaxis
- It shortens the APTT to unmeasurably short and invalidates all one-stage clotting-factor assays - use a bovine chromogenic assay to measure FVIII or the inhibitor
Eradication: immune tolerance induction (ITI) - daily high-dose FVIII for months to years; success ~60-80%, best with a peak historical titre <200 BU and starting titre <10 BU
Acquired haemophilia - bypassing agent for bleeding plus immunosuppression (steroid +/- cyclophosphamide or rituximab) to eradicate the antibody; investigate for underlying malignancy
Gene therapy (valoctocogene roxaparvovec) is available for selected adults without inhibitors

3 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.